Provectus Biopharmaceuticals, Inc. (PVCT): Revenue

Annual figures by period end, from SEC filings.

$336.1K

Year ended 2025-12-31

-30.2%

3-year compound annual growth

2022-12-31 Revenue (USD) 2025-12-31

Period ended	Revenue	Change YoY	Source filing
2025-12-31	$336.1K	-45.5%	2026-03-26, From 2025-01-01
2024-12-31	$617.1K	+10.7%	2026-03-26, From 2024-01-01
2023-12-31	$557.7K	-43.6%	2025-03-28, From 2023-01-01
2022-12-31	$989.0K	n/a	2024-03-28, From 2022-01-01

Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Revenue	Change YoY
Provectus Biopharmaceuticals, Inc. (PVCT)	2025-12-31	$336.1K	-45.5%
Allarity Therapeutics, Inc. (ALLR)	2025-12-31	$320.0K	n/a
Vyome Holdings, Inc (HIND)	2025-12-31	$319.7K	+24.4%
Abvc Biopharma, Inc. (ABVC)	2025-12-31	$296.0K	-41.9%
America Great Health (AAGH)	2025-06-30	$391.7K	+32.9%
Can-Fite BioPharma Ltd. (CANF)	2025-12-31	$405.0K	-39.9%
Medicinova Inc (MNOV)	2025-12-31	$409.7K	n/a
Scienture Holdings, Inc. (SCNX)	2025-12-31	$431.6K	+215.9%
Regen BioPharma Inc (RGBP)	2025-09-30	$236.6K	0.0%

Compare PVCT, ALLR, HIND, ABVC side by side · Screen every company in Pharmaceutical Preparations ↗